Background: Primary intraocular lymphoma (PIOL) is an uncommon subset of primary central nervous system lymphoma. Because it is rare and difficult to diagnose, the natural history and optimal management are unknown.
introduction
Primary intraocular lymphoma (PIOL) is a rare hematopoietic tumor that arises in the retina, vitreous, subretinal pigment epithelial space or optic nerve head [1] . It is an uncommon subset of primary central nervous system lymphoma (PCNSL) that has been reported to have a high risk of ocular and central nervous system (CNS) relapse. Statistical data regarding the incidence of PIOL is lacking, but it has been estimated that in the past 3 years there were at least 100 new cases in the United States [2] . At presentation, PIOL is often misdiagnosed as uveitis and may respond initially to corticosteroids, resulting in a delay of definitive diagnosis [3] . Often a diagnosis is not made until there is brain progression at which time the prognosis is poor. Because the disease is rare and difficult to diagnose, true incidence and natural history are not well characterized. Optimal treatment is unknown, and a variety of local ocular and systemic therapies have been reported. Local ocular treatments include ocular radiotherapy (RT) [4, 5] and intravitreal methotrexate [6] . Extensive treatments include whole brain RT (which includes the posterior retina) as well as intravenous and/or intrathecal chemotherapy.
The International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) is a multidisciplinary group from North America, Europe, and Australia established in 2002 under the sponsorship of the International Extranodal Lymphoma Study Group. Given its rarity, PIOL was identified as an area for which collaborative work would further understanding of the disease [7] . 
statistical considerations
Progression-free survival (PFS) and overall survival (OS) were calculated from date of ocular lymphoma diagnosis to date of first relapse, progression, or death. Surviving patients were censored at date of last follow-up. Survival curves were drawn using the Kaplan Meier productlimit method [8] , and comparisons were examined by the log rank test. Analysis of discrete variables was performed using the v 2 method with
Yates correction for expected values less than 5. Given the descriptive nature of this analysis, there were no a priori power estimates.
results

clinical features
A total of 83 patients were identified; all had disease confined to the eyes at diagnosis with no evidence of brain, systemic or spinal cord lymphoma. Twenty-nine cases included in this cohort were previously reported [9] [10] [11] [12] . Patient characteristics and diagnostic details are summarized in Table 1 . The median age at diagnosis was 63 (24-85) years; 57% were women. The median Eastern Cooperative Oncology Group performance status was 0; only three patients had a score greater than 1. Fifteen patients had a prior malignancy other than lymphoma; the site of origin was available for nine patients and included breast, squamous cell of the pharynx, papillary thyroid, immunocytoma, renal (two), skin, cutaneous T-cell lymphoma and melanoma. All patients had a histological diagnosis of lymphoma. Eighty patients were diagnosed on the basis of vitrectomy (74) or direct choroidal/retinal biopsy (6) . One patient with a positive slit lamp exam was diagnosed by positive cerebrospinal fluid (CSF) cytology. Two patients were initially diagnosed with ocular lymphoma by slit lamp/ophthalmic exam and definitive pathology was not obtained until time of tumor progression and brain biopsy. Specific histological subtypes included large B-cell (55), T-cell (five), subtype not specified (seven); 16 pathology reports were not available for review.
The mean duration of symptoms prior to diagnosis was 6 months (0-36). The presenting symptoms were blurred vision in 33 patients, decreased visual acuity in 23, floaters in 19 and not specified in 20. Data regarding the incidence of bilateral versus unilateral disease were unavailable. Neuro-imaging (enhanced brain MRI or CT scan) showed no evidence of intracranial tumor at diagnosis of intraocular lymphoma. Sixty patients had a staging lumbar puncture performed which revealed positive CSF cytology in nine patients (15%).
therapeutic management
Treatment details are summarized in Table 2 . Forty-four patients received either systemic or intraocular steroids; however, the response was rarely evaluated. Twenty-three received only local ocular therapy at diagnosis and 53 received more extensive treatment including various combinations of systemic chemotherapy, ocular chemotherapy, whole brain radiotherapy (WBRT), and ocular RT. Systemic chemotherapy was methotrexate-based in 37 (70%). All patients with positive CSF cytology received more extensive treatment including systemic chemotherapy in nine, intrathecal chemotherapy in four and WBRT in one. Six patients received no definitive treatment and complete treatment details were unavailable in one. Median follow-up of surviving patients was 32 months.
outcome Median PFS and OS for the entire cohort were 29.6 and 58 months, respectively (Figure 1 ). Excluding those patients with positive CSF cytology did not significantly impact the survival analysis. There was no statistically significant difference in PFS or OS regardless of the treatment modality (Figures 2 and 3) . At last follow-up, 33 patients had died. The cause of death was CNS lymphoma (19), other cancer (3), pneumonia (one), stroke (one), neurotoxicity (one) and unknown (eight).
Forty-seven patients (56%) relapsed at a median of 19 months (0.5-180) after initial therapy. Risk of relapse was similar in the two treatment groups; 56% of those in the Information on treatment-related neurotoxicity was available in 45 patients. The complications reported included none (37), dementia (three), leukoencephalopathy (two), gait disorder (one), hemiparesis (one) and stroke (one). All patients with treatment-related neurotoxicity received more extensive therapy either at diagnosis or relapse. Ocular sequelae were reported in 20 patients; 32% of patients who received ocular RT had a reported complication and 36% of those who received intraocular chemotherapy had a reported complication. These included decreased visual acuity (seven), cataracts (seven), retinopathy (two), dry eyes (one), glaucoma (one), retinal artery occlusion (one) and amaurosis (one).
discussion
Because of its rarity, PIOL has been a difficult disease to study. In previously published series, patients with isolated ocular lymphoma were reported as a subset of patients with ocular involvement from brain lymphoma or at ocular relapse of brain or systemic lymphoma [4, [10] [11] [12] . This report represents the largest exclusive series of PIOL in the literature to date. The average duration of symptoms preceding definitive diagnosis was only 6 months; this is substantially shorter than the 13-24-month latency reported in other series [10, 12] . However, our results support other studies in the literature that suggest that definitive diagnosis could be established in 80% of patients between 6 and 12 months [11, 13] . Vitrectomy was the procedure most frequently used to make a definitive diagnosis. The most common immunophenotype observed was B-cell; however, a small percentage of patients had a primary T-cell PIOL. This distribution is similar to that seen in brain lymphoma.
Extent-of-disease workup found positive CSF cytology in nine of 60 (15%) patients at the time of ocular lymphoma diagnosis. We included these nine patients with concomitant CSF and ocular lymphoma in this report to underscore the need for complete extent-of-disease evaluation [15] . If CSF dissemination is not diagnosed and treated as part of the initial disease process, it will persist as a reservoir of untreated lymphoma that will compromise disease control and survival. Moreover, these nine patients had a similar prognosis and pattern of treatment failure as the rest of the group so that inclusion did not impact our analysis.
Optimally, treatment of PIOL should eradicate disease in the eye and prevent spread to the brain, CSF or systemic compartments. The patients included in this series received a heterogeneous array of treatments. The more focused therapy may have been chosen to minimize toxicity, while more extensive therapy was likely chosen to eradicate microscopic, and otherwise undetectable sites of systemic or CNS lymphoma. Our comparison of these two general treatment strategies did not reveal any significant difference with regard to sites of relapse, PFS or OS. Comparison of more specific elements of treatment (e.g. dose or intrathecal administration of methotrexate) was not possible in this retrospective data set with limited sample size for specific treatment paradigms.
Previous reports have suggested that approximately 80% of patients with PIOL will subsequently develop brain lymphoma [13, 16, 17] . In our series, only 56% of patients ultimately progressed. While it is possible that this is an underestimate because of incomplete follow up and the limits of retrospective data, this suggests that some fraction of patients may achieve prolonged control with or without aggressive initial therapy. It may be that patients with PIOL have a relatively less aggressive form of lymphoma than patients presenting with brain lymphoma, or that a much smaller volume of disease is required within the eye to produce symptoms, resulting in earlier presentation. The majority of patients failed in the brain and eyes (92%); however, 8% relapsed systemically. Our data underscores the need for ongoing careful follow-up of all patients treated for PIOL. Patients should have routine follow-up eye examinations, as well as neurological follow-up with periodic MRI scans and prompt investigation of new systemic symptoms.
This study has several limitations. Our data was based on retrospective information abstracted from the medical records by the submitting physician. Patient evaluation and management were heterogeneous across the participating institutions; while this accurately reflects the varied approach to PIOL in academic and community practices, it limits our ability to perform detailed analyses. Central review of pathology was not possible; however, all centers submitting cases have expert lymphoma pathologists who reviewed or confirmed the diagnosis on submitted cases.
In summary, PIOL is a rare subset of PCNSL with a high risk of relapse in the brain and/or eyes despite treatment. Specific treatment recommendations cannot be made on the basis of this analysis; however, our results suggest that focused ocular therapy with close patient follow-up at the completion of active therapy and deferral of more aggressive therapy, such as WBRT or systemic chemotherapy to time of tumor progression may be appropriate. This strategy has the advantage of minimizing or delay treatment-associated toxicity, and does not appear to compromise disease control or survival. Perhaps most importantly, this report highlights the need for ongoing international collaboration to further our understanding and management of rare malignancies such as PIOL.
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